The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.
Marie-Helene Lafeuille
Consultant or Advisory Role - Janssen
Amanda M. Grittner
Consultant or Advisory Role - Janssen
Patrick Lefebvre
Consultant or Advisory Role - Janssen
Lorie Ellis
Employment or Leadership Position - Janssen
Stock Ownership - Janssen
R. Scott McKenzie
Employment or Leadership Position - Janssen
Stock Ownership - Janssen